Treatment of Staphylococcus aureus Mu50 infections in humans where dosages have from 1 mg/kg to 25 mg/kg NDISACC-(4-(4-chlorophenyl)benzyl)A82846B

摘要

The use of NDISACC-(4-(4-chlorophenyl)benzyl)A82846B, or a salt thereof, in the preparation of a medicament for treating host animals suffering a bacterial infection attributable to methicillin resistant Staphylococcus aureus (strain Mu50) which has reduced glycopeptide sensitivity and is Van A and Van B negative. N-(4-(4-chlorophenyl)benzyl) A82846B and salts thereof are described in published EPO 0667353, which is incorporated herein by reference.